Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-056190
Filing Date
2021-11-10
Accepted
2021-11-10 16:11:10
Documents
57
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rain-10q_20210930.htm   iXBRL 10-Q 2249614
2 EX-31.1 rain-ex311_6.htm EX-31.1 20070
3 EX-31.2 rain-ex312_7.htm EX-31.2 20104
4 EX-32.1 rain-ex321_8.htm EX-32.1 12946
  Complete submission text file 0001564590-21-056190.txt   7792749

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rain-20210930.xsd EX-101.SCH 51658
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rain-20210930_cal.xml EX-101.CAL 42696
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rain-20210930_def.xml EX-101.DEF 214829
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE rain-20210930_lab.xml EX-101.LAB 428873
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rain-20210930_pre.xml EX-101.PRE 333144
10 EXTRACTED XBRL INSTANCE DOCUMENT rain-10q_20210930_htm.xml XML 1313948
Mailing Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560
Business Address 8000 JARVIS AVENUE SUITE 204 NEWARK CA 94560 (510) 953-5559
Rain Therapeutics Inc. (Filer) CIK: 0001724979 (see all company filings)

EIN.: 821130967 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40356 | Film No.: 211396682
SIC: 2834 Pharmaceutical Preparations